^
Association details:
| Biomarker: | S100A8 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study
Published date:
01/22/2021
Excerpt:
High expression of S100A8 (HR = 6.56, 95% CI: 1.67–25.79, P = .0021), S100A16 (HR = 4.55, 95% CI: 1.39–14.86, P = .006) were represented worse survival in liver cancer after Sorafenib treatment.
DOI:
10.1097/MD.0000000000024135
